RxDoctor Payments Data

Elizabeth Mones, MD

Family Medicine · Miami, FLNPI 1023204104

Payments from drug & device makers

$2,234,038in general payments, 2019–2025

Across 145 payments — averaging $15,407 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$772K
  • Pfizer$507K
  • Biohaven Pharmaceuticals, Inc.$321K
  • GSK$208K
  • Chiesi USA, Inc.$129K
  • Genentech, Inc.$105K
  • plus $192K from 4 others

What the payments were for

  • Food & beverage$731100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,234,038 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$3,799
Medicare patients
12
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban161$155,934
JanumetSitagliptin Phos/Metformin Hcl47$35,810
JardianceEmpagliflozin28$29,235
FarxigaDapagliflozin Propanediol19$19,632
LinzessLinaclotide32$16,670
XareltoRivaroxaban12$12,030
LumiganBimatoprost25$11,601
MyrbetriqMirabegron17$10,119
EntrestoSacubitril/Valsartan13$8,613
Fluticasone-SalmeterolFluticasone Propion/Salmeterol46$7,086
Novolog FlexpenInsulin Aspart32$5,964
NovologInsulin Aspart30$4,529
Atorvastatin Calcium669$4,269
SymbicortBudesonide/Formoterol Fumarate11$4,065
Losartan Potassium449$3,672

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$506,611$155,934161 claims
AstraZenecaFarxiga, Symbicort$14,213$23,69730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →